sermorelin

FDA-approved GH peptide for pediatric growth hormone deficiency in 1997. now anti-aging clinics use it for adults. cheaper than HGH.

tier A · growth hormone · FDA '97 Geref · pediatric GHD

verdict

FDA-approved for pediatric growth hormone deficiency in 1997. anti-aging clinics adopted it for adults. gentler than HGH and cheaper.

if you're asking whether sermorelin replaces HGH for adult use — it isn't approved for that, and the rationale clinics offer is mechanistic, not trial-based. sermorelin fires a single natural GH pulse through the GHRH receptor and lets somatostatin feedback cap the response. that's why anti-aging practices like it. pituitary feedback stays intact, the GH axis doesn't flatten the way it can with exogenous HGH. modern controlled trials in healthy adults are minimal.

if you're asking about the pediatric on-label use — Geref carried the 1990 diagnostic NDA and the 1997 therapeutic NDA for pediatric GHD. that's where the FDA history sits. dosing in the labels was developed for children whose GH axis wasn't producing enough pulses. extrapolating those doses to a 50-year-old chasing recovery is pharmacology, not evidence.

if you came in expecting HGH-tier results — users report better sleep within weeks and slow body-composition shifts over months. the GH bump is real and measurable and capped. sermorelin won't produce the supraphysiological GH levels exogenous HGH does. the pharmacology supports modest, slow effects.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why A-tier

the original FDA-approved GHRH analog. 29-amino-acid sequence matching native human GHRH (1-29), the shortest fully functional fragment. approved twice by FDA: as a diagnostic in 1990 (NDA 19-863) and for pediatric GH deficiency in 1997 as Geref (NDA 20-443). EMD Serono pulled commercial production in 2008, explicitly NOT for safety. FDA confirmed in 2013 the withdrawal was commercial. now compounding pharmacies only. A-tier: an FDA approval history no other peptide in its class can claim, but no current commercial product and the approval was narrowly pediatric.

the core tension

FDA-approved in 1997 and validated in pediatric trials. EMD Serono pulled it in 2008, not for safety or efficacy, but because the approved-pediatric-GHRH market was too small to keep producing. compounding pharmacies preserved it. anti-aging clinics adopted it. the original FDA approval still stands on its pharmacology.

what it is

the first 29 amino acids of human GHRH, the shortest fragment that fully binds the GHRH receptor. FDA-approved twice as Geref. once in 1990 as a diagnostic, again in 1997 for pediatric growth hormone deficiency. EMD Serono pulled it in 2008 for commercial reasons, not safety. compounding pharmacies are the only path now.

what it does

binds the GHRH receptor on pituitary somatotrophs and fires a single natural pulse of growth hormone. half-life is about 6 minutes IV. the response is transient by design, and somatostatin feedback still caps the GH bump versus straight HGH.

origin

EMD Serono built it, the US arm of Germany's Merck KGaA. orphan drug status in 1988, two FDA approvals, then a quiet exit as recombinant HGH took the pediatric endocrinology market. in 2013 the FDA confirmed the withdrawal was not for safety or efficacy. that is the quiet legal reason compounding pharmacies still have legs.

why researchers are interested

anti-aging clinics like it because it is gentler than HGH, keeps pituitary feedback intact, and carries the only real FDA history in its class. users report better sleep within weeks and slow body composition shifts over months. it does not flatten the GH axis the way exogenous HGH can.

does it work

in pediatric GHD, yes. that is what the 1997 approval rests on. in adults without documented deficiency, which is what clinics actually sell it for, the data thins out. modern controlled trials in healthy adults are minimal. the pharmacology is the same pharmacology that worked in kids who needed it. extrapolating to a 50-year-old chasing recovery is mechanism, not evidence. expect modest, slow effects or expect to be disappointed.

claims vs the data

• stimulates natural pulsatile GH release — supported — short 6-min half-life means the GH response is transient and mirrors natural pulse pattern. this was well-documented in the pediatric GHD approval trials.
• FDA-approved for pediatric growth hormone deficiency — partially true — was FDA-approved as Geref 1997-2008. currently no active FDA approval, Geref is on the Discontinued Drug Product List.
• safer than HGH for adults — partially true — preserves pituitary feedback and produces a transient GH pulse rather than direct exogenous GH exposure. but sermorelin is not approved for adult use, and the adult safety claim is inference from mechanism.
• effective in adult anti-aging contexts — weak — no FDA-approved adult indication. compounding-based off-label use in functional medicine, but controlled trials in healthy adults are minimal.
• compounded sermorelin is FDA-approved — contradicted — FDA does not review compounded medications. compounding pharmacies have legal standing because Geref was once approved, but the compounded product itself is not FDA-reviewed.
• discontinued because of safety problems — contradicted — FDA explicitly determined in 2013 that Geref was NOT withdrawn for safety or effectiveness reasons. discontinuation was commercial.

key facts

• molecular formula: C₁₄₉H₂⁤⁤N₄₄O₄₀S
• molecular weight: 3357.9 g/mol
• amino acids: 29 (GHRH 1-29)
• half-life: ~6 minutes (IV); somewhat longer subQ
• type: GHRH analog (shortest fully functional fragment)
• CAS: 86168-78-7
• 1990 first FDA approval (diagnostic)
• 1997 pediatric GHD approval (geref)
• 2008 voluntarily discontinued
• ~6 min IV half-life (short by design)

frequently asked questions

What is sermorelin?

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), the bioactive portion of the natural GHRH molecule. It binds the GHRH receptor in the pituitary to stimulate endogenous growth hormone release.

What does sermorelin do?

Sermorelin stimulates the pituitary gland to release natural growth hormone in a pulsatile pattern that mimics physiological GH secretion. Clinical trials established efficacy for pediatric growth hormone deficiency. Community users, typically aging adults, report improved sleep quality, recovery, and body composition changes over months of consistent use.

How is sermorelin typically administered?

The historical Geref label, withdrawn in 2008, describes pediatric growth hormone deficiency use. There is currently no FDA-approved sermorelin product for adults. Off-label hormone-clinic use exists, but no controlled clinical trials support a specific adult-use framework.

What are the side effects of sermorelin?

Common side effects include injection-site reactions, occasional flushing, headaches, and altered sense of taste. Its historical pediatric label gives more safety context than most clinic peptides, but adult anti-aging use does not have the same approval-grade dataset. Somatostatin feedback limits GH response compared with exogenous HGH, but that is not a substitute for adult route-specific dosing and safety data.

Is sermorelin FDA approved?

Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency. It was voluntarily withdrawn from the US market in 2008 due to manufacturing/supply issues, not safety or efficacy concerns. It remains widely prescribed today through compounding pharmacies via hormone clinics.

How much does sermorelin cost?

No FDA-approved sermorelin product is sold today. Compounded prescription sermorelin from hormone clinics typically costs $200-500 per month depending on dose and clinic. Research-grade material is priced separately and is not for human use.

related peptides

• cjc-1295 — longer-acting GHRH analog derived from sermorelin
• tesamorelin — modified GHRH, FDA-approved for HIV lipodystrophy
• ipamorelin — GHRP, different mechanism, often stacked
• hgh — the direct GH it indirectly produces

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.